{
  "id": 6616150,
  "title": "Rocket Pharmaceuticals at cantor healthcare conference: cardiomyopathy focus",
  "url": "https://urgent.news/2026/09/10/rocket-pharmaceuticals-at-cantor-healthcare-conference-cardiomyopathy",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-10T17:49:47.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/rocket-pharmaceuticals-at-cantor-healthcare-conference-cardiomyopathy-focus-93CH-4896655"
  },
  "original_language": "en",
  "account": "On Thursday, September 10, 2026, Rocket Pharmaceuticals (RCKT) highlighted a focused approach centered on rare genetic cardiomyopathies during the 12th Annual Cantor Fitzgerald Global Healthcare Conference. The company shared updates on its Danon disease program, which has overcome earlier safety concerns, while acknowledging the ongoing challenges in patient identification, trial design, and commercial execution. Rocket's shares were trading at $3.46, a 4.61% decrease from the prior close of $3.63, and the stock remained within its 52-week range of $2.53 to $5.45. The firm's market capitalization stood at $381 million, trading below the InvestingPro Fair Value of $4.15, indicating potential undervaluation.\n\nRocket Pharmaceuticals is concentrating on three clinical cardiomyopathy programs: Danon disease, PKP2-related arrhythmogenic cardiomyopathy, and BAG3-related dilated cardiomyopathy. The company reported successful treatment of three Danon disease patients using a recalibrated dose of 3.8 E13 vector genomes per kilogram, with positive safety and tolerability outcomes. The company's first approved product, KRESLADI for severe LAD-I, is set for release in the fourth quarter of 2024.\n\nDespite the progress, patient identification remains a significant challenge, with only 10% to 20% of U.S. centers currently conducting genetic testing for Danon disease. Rocket's strategy emphasizes programs with clear mechanisms of action, high unmet medical needs, and realistic paths to clinical results and regulatory approval. CEO Gaurav Shah emphasized the company's focus on genetic cardiomyopathy programs, including Hypertrophic cardiomyopathy (through Danon disease), Arrhythmogenic cardiomyopathy (PKP2 program), and Dilated cardiomyopathy (BAG3 program).\n\nRocket is actively pursuing partnerships for its LAD-I, Fanconi anemia, and PKD programs, allowing the company to concentrate on its core cardiomyopathy focus. The firm maintains a robust balance sheet with a current ratio of 9.24 and minimal debt, employing substantial cash reserves to support its multi-program development strategy, despite annual cash burn of approximately $170 million. Management highlighted the \"Goldilocks zone\" for AAV-based cardiac gene therapy, positioning the 3.8 E13 dose as optimal for efficacy and safety. Discussions with the Food and Drug Administration (FDA) about the pivotal Danon study design are ongoing, with potential adjustments based on agency feedback. Rocket is also developing a no-cost genetic testing program, Mission: Genome, to streamline the diagnosis process and address administrative burdens. The ICD-10 code for Danon disease has been available for 29 months, showing positive uptake. The company is positioned to launch KRESLADI for severe LAD-I in the fourth quarter of 2024, with pricing strategies aimed at aligning with other gene therapies and the long-term costs of untreated LAD-I.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}